	US 12,161,676 B2
	Methods of use of islet cells
Clive Svendsen, Pacific Palisades, CA (US); and Dhruv Sareen, Porter Ranch, CA (US)
Assigned to Cedars-Sinai Medical Center, Los Angeles, CA (US)
Appl. No. 16/982,691
Filed by CEDARS-SINAI MEDICAL CENTER, Los Angeles, CA (US)
PCT Filed Mar. 22, 2019, PCT No. PCT/US2019/023749 § 371(c)(1), (2) Date Sep. 21, 2020, PCT Pub. No. WO2019/183597, PCT Pub. Date Sep. 26, 2019.
Claims priority of provisional application 62/647,548, filed on Mar. 23, 2018.
Prior Publication US 2021/0000880 A1, Jan. 7, 2021
Int. Cl. A61K 35/39 (2015.01); C12N 5/071 (2010.01)

CPC A61K 35/39 (2013.01) [C12N 5/0678 (2013.01); C12N 2501/115 (2013.01); C12N 2501/119 (2013.01); C12N 2501/15 (2013.01); C12N 2501/155 (2013.01); C12N 2501/165 (2013.01); C12N 2501/999 (2013.01); C12N 2506/45 (2013.01)]

15 Claims

1. A method of generating pancreatic progenitor cells, comprising:

culturing induced pluripotent stem cells (iPSCs) in the presence of Activin A and CHIR99021 for about 3 days to generate definitive endoderm;

culturing definitive endoderm in the presence of FGF10, Noggin, and CHIR 99021 for about 2 days to generate gut tube endothelium; and

culturing gut tube endothelium in the presence of FGF10, Noggin, Sant1, and retinoic acid for about 4 days to generate pancreatic progenitor cells.